Search research articles
Contact Us
Filters
Showing results (191-200 of 199) with videos related to
Page
of 20
Sort By:
You have reached the last page of results.
This site can display upto 199 results.
Nature Communications
|
March 13, 2026
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study
Yonina R Murciano-Goroff, Antoine Hollebecque, Rebecca S Heist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 21, 2020
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib
Ezra Y Rosen, Melissa L Johnson, Sarah E Clifford, et al.
The New England Journal of Medicine
|
April 30, 2015
Rociletinib in EGFR-mutated non-small-cell lung cancer
Lecia V Sequist, Jean-Charles Soria, Jonathan W Goldman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 29, 2020
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
Benjamin J Solomon, Lavinia Tan, Jessica J Lin, et al.
JCI Insight
|
January 23, 2026
EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
Atsuko Ogino, Amir Vajdi, Xinmeng Jasmine Mu, et al.
JCO Precision Oncology
|
April 10, 2025
Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study
Takao Fujisawa, Yoshiaki Nakamura, Hideaki Bando, et al.
Science Translational Medicine
|
September 13, 2021
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of <i>EGFR</i>-mutant lung cancer
Pınar Özden Eser, Raymond M Paranal, Jieun Son, et al.
The New England Journal of Medicine
|
August 27, 2020
Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer
Alexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, et al.
JCI Insight
|
November 25, 2016
Institutional implementation of clinical tumor profiling on an unselected cancer population
Lynette M Sholl, Khanh Do, Priyanka Shivdasani, et al.
Page
of 20
Search research articles
Search
Showing results (191-200 of 199) with videos related to
Sort By:
Page
of 20
You have reached the last page of results.
This site can display upto 199 results.
Nature Communications
|
March 13, 2026
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study
Yonina R Murciano-Goroff, Antoine Hollebecque, Rebecca S Heist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 21, 2020
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib
Ezra Y Rosen, Melissa L Johnson, Sarah E Clifford, et al.
The New England Journal of Medicine
|
April 30, 2015
Rociletinib in EGFR-mutated non-small-cell lung cancer
Lecia V Sequist, Jean-Charles Soria, Jonathan W Goldman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 29, 2020
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
Benjamin J Solomon, Lavinia Tan, Jessica J Lin, et al.
JCI Insight
|
January 23, 2026
EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
Atsuko Ogino, Amir Vajdi, Xinmeng Jasmine Mu, et al.
JCO Precision Oncology
|
April 10, 2025
Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study
Takao Fujisawa, Yoshiaki Nakamura, Hideaki Bando, et al.
Science Translational Medicine
|
September 13, 2021
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of <i>EGFR</i>-mutant lung cancer
Pınar Özden Eser, Raymond M Paranal, Jieun Son, et al.
The New England Journal of Medicine
|
August 27, 2020
Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer
Alexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, et al.
JCI Insight
|
November 25, 2016
Institutional implementation of clinical tumor profiling on an unselected cancer population
Lynette M Sholl, Khanh Do, Priyanka Shivdasani, et al.
Page
of 20